Adoptive immunotherapy for adenovirus (AdV)-associated complications post transplantatio

Completed

• Conditions: Pediatric patients with ALL, AML, CML or MDS following hematopoietic stem cell transplantation; Cancer; Paediatric leukaemia

• Registration Number: ISRCTN14732774
• Lead Sponsor: Charité - University Medicine Berlin (Germany)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-03-31
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 306

Inclusion Criteria

Pediatric patients, aged 2 to 18 years with:
1. Acute leukemias (ALL)
2. Acute myeloid leukemia (AML)
3. Chronic myeloid leukemia (CML)
4. Myelodysplastic syndromes (MDS)

Exclusion Criteria

1. Patients in relapse or progress of AML or ALL and blast crisis of CML at the time of randomization
2. All second transplants
3. AdV seronegative recipients with seronegative matched related donors (MRD)
4. Patients with severe non-hematopoietic organ toxicity grade 3-5 (according to the National Cancer Institute [NCI] and Cancer Therapy Evaluation Program [CTEP] reporting criteria) at the time of randomization

Study & Design

• Study Type: Interventional
• Study Design: Not specified